Related Experiment Video
Updated: Jul 18, 2026
Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, which selectively induces apoptosis in many transformed cells without apparent toxic side effects in normal tissue. We recently described the construction and characterization of a lentiviral vector for expression of TRAIL. In this report, we evaluate its suitability for therapeutic application. In vitro, we observed specific induction of apoptosis upon transduction in human lung cancer cells. Cell death was partially dependent on successful integration and TRAIL expression by the vectors, but was to some extent mediated by protein carryover, as we found TRAIL protein associated with virus particles. Transduction of subcutaneously growing lung tumors on nude mice with lentiviral TRAIL mediated a transient suppression of tumor growth. Analysis of tumor sections revealed that transduction efficiency of lentiviral control vector but not of lentiviral TRAIL vector was high. This was because of the direct cytotoxic activity of recombinant TRAIL present in viral particles, which prevented efficient tumor transduction. These data therefore suggest that enveloped viral vectors constitutively expressing TRAIL are well suited for ex vivo applications, such as the transduction of tumor-homing cells, but may have a lower effect when used directly for the transduction of tumor cells in vivo.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy by inducing apoptosis in cancer cells. Lentiviral TRAIL vectors are effective ex vivo but less so in vivo due to direct cytotoxicity.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells.
- Lentiviral vectors offer a platform for delivering therapeutic genes.
- Evaluating TRAIL-expressing lentiviral vectors for cancer treatment is crucial.
Purpose of the Study:
- To assess the therapeutic potential of lentiviral vectors expressing TRAIL for cancer treatment.
- To investigate the efficacy of TRAIL delivery in vitro and in vivo.
- To determine the optimal application strategy for lentiviral TRAIL vectors.
Main Methods:
- Construction and characterization of a lentiviral vector for TRAIL expression.
- In vitro transduction of human lung cancer cells.
- In vivo studies using nude mice with subcutaneous lung tumors.
- Analysis of tumor sections for transduction efficiency and apoptosis induction.
Main Results:
- Lentiviral TRAIL induced apoptosis in human lung cancer cells in vitro.
- TRAIL protein associated with viral particles contributed to cell death.
- In vivo, lentiviral TRAIL mediated transient tumor growth suppression.
- Direct cytotoxicity of viral TRAIL limited tumor transduction efficiency in vivo.
Conclusions:
- Lentiviral TRAIL vectors are suitable for ex vivo applications, such as transducing tumor-homing cells.
- Direct in vivo transduction of tumor cells with lentiviral TRAIL may be less effective due to pre-transduction cytotoxicity.
- Further research into optimizing delivery methods for in vivo applications is warranted.
More Related Videos
Related Concept Videos
01:17The Extrinsic Apoptotic Pathway
01:31The Intrinsic Apoptotic Pathway
01:30Apoptosis